

# FOR IMMEDIATE RELEASE

## Medicinal Genomics Corporation and Courtagen Life Sciences Announce CannMed 2016, the Personalized Cannabinoid Medicine Conference, April 10-11, 2016

*CannMed 2016 Personalized Cannabinoid Medicine Conference will convene leaders in research, medicine, and therapeutics to discuss real-world issues around cannabis-based therapies for neurological disorders*

WOBURN, MA. January 13<sup>th</sup>, 2016, Medicinal Genomics Corporation and Courtagen Life Sciences, Inc. today announced that they will host the inaugural CannMed 2016 Personalized Cannabinoid Medicine Conference to be held on April 10<sup>th</sup> and 11<sup>th</sup> in Boston, MA. The conference will be the first to focus on the intersection of clinical application, medical research, and cannabis based therapeutics related to neurological disorders, such as epilepsy, developmental delay, chronic and neuropathic pain, Alzheimer's, Parkinson's, traumatic brain injury, as well as other disease areas.

The conference will open with a dinner reception on Sunday, April 10<sup>th</sup>, followed by a full day program on Monday, April 11<sup>th</sup> at the Joseph B. Martin Conference Center at the Harvard School of Medicine. An exciting slate of invited speakers representing the medical and research communities will be presenting, including Dr. Raphael Mechoulam, professor of Medicinal Chemistry at the Hebrew University of Jerusalem, the research pioneer who discovered the endocannabinoid system and key active components of cannabis; and Dr. Orrin Devinsky, Professor of Neurology, Neurosurgery and Psychiatry Director, NYU Comprehensive Epilepsy Center, a leader in research and treatment of epilepsy.

“We are witnessing the creative destruction of 20th century medicine. The tsunami of personalized medicine and genomics is colliding with a perfect storm of over-the-counter and pharmaceutical-produced cannabinoid therapies,” says Kevin McKernan, Chief Scientific Officer of Medicinal Genomics and Courtagen Life Sciences, “CannMed 2016 is focused on unveiling the technological progress in these high growth rate industries.”

The full program will include talks and posters on a range of topics related the role of the endocannabinoid system in the treatment of neurological disorders. Presenters from the fields of research, medical practice, and therapeutic development and production are welcome to submit abstracts by February 15<sup>th</sup> for oral or poster presentations. A small number of sponsor slots remain available as well.

Registration is currently open for attendees, with early-bird discounts available until January 31. For information, registration, and abstract submissions, please visit <http://www.medicinalgenomics.com/CannMed2016/>

### **About Medicinal Genomics Corporation**

Medicinal Genomics Corporation applies state-of-the-art life science technology to Cannabis plant genetics. Our products help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics utilizes a highly sophisticated Next Generation Sequencing laboratory, bioinformatics system, and DNA based technologies to deliver unmatched technical solutions to decipher the genetic code and quality level of medicinal Cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit <http://www.medicinalgenomics.com/>

### **About Courtagen Life Sciences, Inc.**

Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business.

== MORE ==

Courtagen's work helps physicians elucidate the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit <http://www.courtagen.com/>

Contact:  
Mike Catalano  
press@medicinalgenomics.com  
877-395-7608

###